NEW YORK (GenomeWeb News) – Atossa Genetics today said that revenues for 2012 increased sharply following the launch of two tests.

Separately, the company also said that it has entered into a $30 million stock purchase agreement with Aspire Capital.

The Seattle-based company brought in revenues of $481,842 in 2012, compared to $1,500 in 2011. Of that total $475,402 resulted from its diagnostic testing service, while $6,440 derived from sales of Atossa's MASCT Systems.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.